Categories: News

Fibrocor Therapeutics Inc. Announces Appointment of Industry Veteran Joseph Walewicz as Chief Financial Officer

TORONTO, ON / ACCESSWIRE / January 6, 2021 / Fibrocor Therapeutics Inc. (“Fibrocor” or “the Company”), a privately held developer of de novo therapeutics to treat fibrotic diseases, announced today the appointment of industry veteran Joseph Walewicz as Chief Financial Officer.

Joseph (Joe) Walewicz has over 25 years of experience in finance, capital markets and business development. Prior to joining Fibrocor, Joe was Executive Vice President of Business and Corporate Development at Clementia Pharmaceuticals, joining the executive team prior to its successful NASDAQ IPO in 2017, and continuing through to IPSEN’s US$1 billion acquisition of Clementia in 2019. Previously, Joe was an executive at two other successful publicly traded biopharma companies, and a ranked investment analyst at major North American investment banks.

“We are very pleased to welcome Joe to the Fibrocor executive team, and we expect that his experience in finance, capital markets and business development will be extremely valuable as we grow and expand our business”, stated Mark Steedman, Chief Executive Officer, Fibrocor.

“I am thrilled to join the team at this critical junction, as Fibrocor’s key discovery programs progress towards clinical development”, commented Joe Walewicz. “I look forward to helping Fibrocor continue to build a world class development team that will advance its clinical programs, while also expanding and accelerating our innovative discovery efforts in fibrotic diseases.”

ABOUT FIBROCOR THERAPEUTICS INC.

Fibrocor is a privately held, tissue specific, drug discovery company. It is pioneering the use of tissue specific therapeutics in the field of precision medicine and in particular, Fibrosis. The company has partnered with leading research institutes in Toronto, Canada, to aggregate and interrogate diseased fibrotic tissue samples in a number of organ systems to understand the genesis of the disease and its manifestations in fast progressing populations. For more information visit fibrocortherapeutics.com.

MEDIA RELATIONS

Julie A. Fotheringham
Partner, HAGEMAN Communications
Julie.fotheringham@hageman.ca
416.951.7988

SOURCE: Fibrocor Therapeutics Inc.

View source version on accesswire.com:
https://www.accesswire.com/622991/Fibrocor-Therapeutics-Inc-Announces-Appointment-of-Industry-Veteran-Joseph-Walewicz-as-Chief-Financial-Officer

Staff

Recent Posts

Real Time Medical Systems Achieves HITRUST Risk-Based, 2-Year Certification Demonstrating the Highest Level of Information Protection Assurance

Company earns recertification, validating commitment to strong cybersecurity protecting sensitive dataBALTIMORE--(BUSINESS WIRE)--Real Time Medical Systems…

3 hours ago

CharmHealth Announces Charmalot 2024 to Innovate, Integrate and Inspire the Healthcare Ecosystem

Annual User Conference and Innovation Challenge Designed to Pioneer the Future of Digital Health and…

3 hours ago

Real Time Medical Systems Achieves HITRUST Risk-Based, 2-Year Certification Demonstrating the Highest Level of Information Protection Assurance

Company earns recertification, validating commitment to strong cybersecurity protecting sensitive dataBALTIMORE--(BUSINESS WIRE)--Real Time Medical Systems…

3 hours ago

CharmHealth Announces Charmalot 2024 to Innovate, Integrate and Inspire the Healthcare Ecosystem

Annual User Conference and Innovation Challenge Designed to Pioneer the Future of Digital Health and…

3 hours ago

Hemostemix Announces Trademark Granted by Switzerland and Interest Payment

Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…

3 hours ago

OpenScholar Announces the Release of Research Dashboards

Findable research is fundable research BOSTON, June 11, 2024 /PRNewswire/ -- OpenScholar announced immediate availability of…

3 hours ago